THE RECENTLY completed, randomized, multi-institutional Urokinase-Pulmonary Embolism Trial, previously described on these pages,1 has demonstrated that a 12-hour infusion of urokinase followed by heparin therapy accelerates the resolution of pulmonary embolism within 24 hours, when compared to heparin therapy alone. This treatment effect favoring urokinase was established by statistically significant differences in 24-hour pulmonary arteriograms, lung scans, and hemodynamic measurements. The treatment difference was noted first in the arteriograms, then with the hemodynamic measurements, and finally in the lung scans. A summary of these findings is shown in table 1. A more detailed report has been submitted to the Journal of the American Medical Association.2 At the conclusion of the trial, 160 patients were studied with a 2-week mortality of 9% in the heparin-treated patients and 7% in the urokinase group. Recurrent pulmonary embolism during this period occurred in 19% and 15% of patients, respectively. Pulmonary embolectomy was not performed in any of these patients. The difference in lung scan resolution between urokinase and heparin-treated patients disappeared by the seventh post-treatment day, but in both treatment groups an average of 25% of the original scan defect remained on follow-up scans at 1 year in the 59 patients on whom these data are presently Circulation, Volume XLII, December 1970 available. The only notable complication of urokinase therapy was overt bleeding which occurred in 45% of the urokinase-treated patients as contrasted to 27% of heparin-treated patients. However, in only one urokinasetreated patient was bleeding severe enough to necessitate premature termination of thrombolytic therapy. Furthermore, the increased bleeding rate seen in urokinase-treated patients was primarily attributable to the invasive procedures necessary to obtain the arteriographic and hemodynamic data.
Eleven patients who entered the trial with massive embolism and in shock had a 2-week mortality of 18%. These particular patients, regardless of treatment, showed a high rate of clinical improvement, but urokinase patients in this group showed dramatic radiographic and hemodynamic responses. Pulmonary embolectomy continues to be a discouraging therapy for these critically ill patients,3 and thrombolytic therapy may well become the preferred treatment, especially in patients with borderline cardiac reserve.
This trial, supported and coordinated by the National Heart and Lung Institute, has accomplished its stated goal-to establish the ability of urokinase to accelerate significantly the resolution of pulmonary emboli. Because of a relatively low death rate in most patients with pulmonary embolism, no significant difference in mortality was expected in the small number of patients studied. A proper evaluation of the effect of thrombolytic therapy on mortality from pulmonary embolism will require a trial which includes a very large number of high-risk patients (patients in shock with massive embolism). However, because of the scarcity of these patients such a study will require many years to complete and as such is not practical. This trial employed a 12-hour urokinase infusion and, although effective, this regimen seldom achieved complete or nearly complete thrombolysis. Since it is likely that doubling the duration of the urokinase infusion will achieve more nearly maximal dissolution of the embolus, a second trial is now in progress to evaluate this possibility and to provide a comparison of urokinase with streptokinasc therapy for pulmonary embolism. 
